Structure of the extracellular region of HER2 alone and in complex with the Herceptin Fab

Nature

Volumn 421, Issue 6924, 2003, Pages 756-760

  Cho, Hyun Soo ^a   Mason, Karen ^b   Ramyar, Kasra X ^a   Stanley, Ann Marie ^a   Gabelli, Sandra B ^a   Denney Jr , Dan W ^b   Leahy, Daniel J ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Genitope Corporation   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CELL CULTURE; CRYSTAL STRUCTURE; MONOCLONAL ANTIBODIES; ONCOLOGY; TISSUE; TUMORS;

CELL PROLIFERATION;

EPIDEMIOLOGY;

EPIDERMAL GROWTH FACTOR; EPIDERMAL GROWTH FACTOR RECEPTOR; IMMUNOGLOBULIN F(AB) FRAGMENT; LIGAND; NEU DIFFERENTIATION FACTOR; TRASTUZUMAB;

CANCER; MEDICINE;

ANIMAL CELL; ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; CELL DIFFERENTIATION; CELL PROLIFERATION; CONTROLLED STUDY; CRYSTAL STRUCTURE; EMBRYO DEVELOPMENT; ENDOCYTOSIS; GENE OVEREXPRESSION; LIGAND BINDING; NONHUMAN; PRIORITY JOURNAL; PROGNOSIS; PROTEIN ANALYSIS; PROTEIN CONFORMATION; PROTEIN DOMAIN; PROTEIN INTERACTION; PROTEIN STRUCTURE; RAT;

ANIMALS; ANTIBODIES, MONOCLONAL; BINDING SITES; BINDING SITES, ANTIBODY; CRYSTALLOGRAPHY, X-RAY; HUMANS; IMMUNOGLOBULIN FAB FRAGMENTS; LIGANDS; MODELS, MOLECULAR; PROTEIN STRUCTURE, TERTIARY; RATS; RECEPTOR, ERBB-2;

ANIMALIA;

EID: 0037434791     PISSN: 00280836     EISSN: None     Source Type: Journal    
DOI: 10.1038/nature01392     Document Type: Article

References (30)

1. Yarden, Y. & Sliwkowski, M. X. Untangling the ErbB signalling network. Nature Rev. Mol. Cell Biol. 2, 127-137 (2001).
2. Olayioye, M. A., Neve, R. M., Lane, H. A. & Hynes, N. E. The ErbB signaling network: receptor heterodimerization in development and cancer. EMBO J. 19, 3159-3167 (2000).
3. Tang, C. K. & Lippman, M. E. in Hormones and Signaling (ed. O'Malley, B. W.) 113-165 (Academic, San Diego, 1998).
4. Slamon, D. J. et al. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 235, 177-182 (1987).
5. Slamon, D. J. et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpress HER2. N. Engl. J. Med. 344, 783-792 (2001).
6. Carpenter, G. Receptors for epidermal growth factor and other polypeptide mitogens. Annu. Rev. Biochem. 56, 881-914 (1987).
7. Schlessinger, J. Cell signaling by receptor tyrosine kinases. Cell 103, 211-225 (2000).
8. Jones, J. T., Akita, R. W. & Sliwkowski, M. X. Binding specificities and affinities of egf domains for ErbB receptors. FEBS Lett. 447, 227-231 (1999).
9. Di Fiore, P. P. et al. erbB-2 is a potent oncogene when overexpressed in NIH/3T3 cells. Science 237, 178-182 (1987).
10. Ogiso, H. et al. Crystal structure of the complex of human epidermal growth factor and receptor extracellular domains. Cell 110, 775-787 (2002).
11. Garrett, T. P. J. et al. Crystal structure of a truncated epidermal growth factor receptor extracellular domain bound to transforming growth factor α. Cell 110, 763-773 (2002).
12. Ferguson, K. M. et al. EGF activates its receptor by relieving auto-inhibition of ectodomain dimerization. Mol. Cell (in the press).
13. Cho, H. S. & Leahy, D. J. Structure of the extracellular region of HER3 reveals an interdomain tether. Science 297, 1330-1333 (2002).
14. Banfield, M. J., King, D. J., Mountain, A. & Brady, R. L. VL:VH domain rotations in engineered antibodies: crystal structures of the Fab fragments from two murine antitumor antibodies and their engineered human constructs. Proteins 29, 161-171 (1997).
15. Lawrence, M. C. & Colman, P. M. Shape complementarity at protein/protein interfaces. J. Mol. Biol. 234, 946-950 (1993).
16. Berezov, A. et al. Disabling receptor ensembles with rationally designed interface peptidomimetics. J. Biol. Chem. 277, 28330-28339 (2002).
17. Harari, D. & Yarden, Y. Molecular mechanisms underlying ErbB2/HER2 action in breast cancer. Oncogene 19, 6102-6114 (2000).
18. Sliwkowski, M. X. et al. Nonclinical studies addressing the mechanism of action of Trastuzumab (Herceptin). Semin. Oncol. 26, 60-70 (1999).
19. Molina, M. A. et al. Trastuzumab (Herceptin), a humanized anti-Her2 receptor monoclonal antibody, inhibits basal and activated Her2 ectodomain cleavage in breast cancer cells. Cancer Res. 61, 4744-4749 (2001).
20. Burke, C. L., Lemmon, M. A., Coren, B. A., Engelman, D. M. & Stern, D. F. Dimerization of the p185neu transmembrane domain is necessary but not sufficient for transformation. Oncogene 14, 687-696 (1997).
21. Denney, D. W. Jr Gene amplification methods. US patent 5,776,746 (1998).
22. Leahy, D. J., Dann, C. E., Longo, P., Perman, B. & Ramyar, K. X. A mammalian expression vector for expression and purification of secreted proteins for structural studies. Protein Expr. Purif. 20, 500-506 (2000).
23. Navaza, J. AMoRe: an automated package for molecular replacement. Acta Crystallogr. A 50, 157-163 (1994).
24. Brunger, A. T. et al. Crystallography & NMR system: a new software suite for macromolecular structure determination. Acta Crystallogr. D 54, 905-921 (1998).
25. Vagin, A. & Teplyakov, A. MOLREP: an automated program for molecular replacement. J. Appl. Crystallogr. 30, 1022-1025 (1997).
26. Jones, T., Zou, J.-Y., Cowan, S. & Kjeldgaard, M. Improved methods for building protein models in electron density maps and the location of errors in these models. Acta Crystallogr. A 47, 110-119 (1991).
27. Winn, M. D., Isupov, M. N. & Murshudov, G. N. Use of TLS parameters to model anisotropic displacements in macromolecular refinement. Acta Crystallogr. D 57, 122-133 (2001).
28. Laskowski, R. A. et al. PROCHECK: a program to check the stereochemical quality of protein structures. J. Appl. Crystallogr. 26, 283-291 (1993).
29. Carson, M. Ribbons. Methods Enzymol. 277, 493-505 (1997).
30. Kraulis, P. J. A program to produce both detailed and schematic plots of protein structures. J. Appl. Crystallogr. 24, 946-950 (1991).